Literature DB >> 30097149

Peripheral neuropathic pain in idiopathic Parkinson's disease: Prevalence and impact on quality of life; a case controlled study.

Joy K Adewusi1, Marios Hadjivassiliou2, Ana Vinagre-Aragón2, Karen Ruth O'Connor3, Aijaz Khan2, Richard Adam Grünewald2, Panagiotis Zis4.   

Abstract

BACKGROUND AND
PURPOSE: Pain is a frequent and debilitating non-motor symptom of Idiopathic Parkinson's Disease (IPD). The present study investigated the prevalence of pain and specifically peripheral neuropathic pain (PNP) in IPD, and ascertained any impact of PNP on quality of life (QoL).
METHODS: Patients with IPD and age- and gender-matched controls were screened for overall pain using the King's Parkinson's Pain Scale (KPPS). PNP was assessed using the Michigan Neuropathy Screening Instrument (MNSI). QoL was assessed using the 36-Item Short Form Survey (SF-36).
RESULTS: Fifty-one patients and 51 age and gender matched controls were recruited. The prevalence of overall pain was similar in the two groups (88.2% versus 94.1%, p = 0.487). However, patients with IPD had higher KPPS scores in fluctuation-related (4.9 ± 6.9 vs 1.1 ± 2.6, p < 0.001), nocturnal (6.6 ± 7.5 vs 1.7 ± 4.2, p < 0.001) and oro-facial (0.6 ± 2.0 vs 0.0 ± 0.0, p = 0.040) domains compared to controls. Patients with IPD experienced more PNP compared to healthy control subjects (35.3% versus 13.7%, p = 0.011). After adjusting for age, gender, disease duration and overall KPSS score, PNP correlated negatively with physical functioning score (beta -0.290, p = 0.036), emotional role limitations score (beta -0.319, p = 0.032) and general health perception score (beta -0.342, p = 0.014) domains of SF-36.
CONCLUSION: Peripheral neuropathic pain is prevalent in IPD and has a significant impact on QoL. The presence of burning pain is suggestive of small fibre neuropathy, but this symptom is not featured in KPSS and, therefore, a revision of the KPSS should be considered.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Idiopathic Parkinson's disease; Non-motor symptoms; Pain; Peripheral neuropathy; Quality of life

Mesh:

Year:  2018        PMID: 30097149     DOI: 10.1016/j.jns.2018.06.022

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

Review 1.  Potential use of corneal confocal microscopy in the diagnosis of Parkinson's disease associated neuropathy.

Authors:  Ning-Ning Che; Hong-Qi Yang
Journal:  Transl Neurodegener       Date:  2020-07-02       Impact factor: 8.014

Review 2.  Tapentadol for neuropathic pain: a review of clinical studies.

Authors:  Ulderico Freo; Patrizia Romualdi; Hans G Kress
Journal:  J Pain Res       Date:  2019-05-16       Impact factor: 3.133

3.  Psychological Aspects and Quality of Life in Chronic Pain.

Authors:  Panagiotis Zis; Giustino Varrassi; Athina Vadalouka; Antonella Paladini
Journal:  Pain Res Manag       Date:  2019-06-12       Impact factor: 3.037

Review 4.  Pain in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis.

Authors:  Athena Michaelides; Robert D M Hadden; Ptolemaios G Sarrigiannis; Marios Hadjivassiliou; Panagiotis Zis
Journal:  Pain Ther       Date:  2019-06-14

Review 5.  Neuro-Immunity and Gut Dysbiosis Drive Parkinson's Disease-Induced Pain.

Authors:  Katiane Roversi; Natalia Callai-Silva; Karine Roversi; May Griffith; Christos Boutopoulos; Rui Daniel Prediger; Sébastien Talbot
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

6.  Pain Assessment in Chinese Parkinson's Disease Patients Using King's Parkinson's Disease Pain Scale.

Authors:  Liang Gao; Weiling Huang; Laisheng Cai; Yufen Peng
Journal:  J Pain Res       Date:  2022-03-10       Impact factor: 3.133

Review 7.  Chronic Pain Treatment Strategies in Parkinson's Disease.

Authors:  Amber Edinoff; Niro Sathivadivel; Timothy McBride; Allyson Parker; Chikezie Okeagu; Alan D Kaye; Adam M Kaye; Jessica S Kaye; Rachel J Kaye; Meeta M Sheth; Omar Viswanath; Ivan Urits
Journal:  Neurol Int       Date:  2020-11-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.